| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea2c0d0dcb67d4a3c3831d91df0d6eb0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a6fea908aa4d7a85990aded520a53480
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_130b17bf22c7fa3bbe73583436654dfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_580da6d76866a123e2418f31b0181ead |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-02 |
| filingDate |
2009-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c57d75fbc136b1b6002437fc3ff68fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2dd84350ad78030dc71fcbd64e51923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39bcc5cd0a8ed12d422b909bfb708f38 |
| publicationDate |
2013-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8445020-B2 |
| titleOfInvention |
High-loading, controlled-release magnesium oral dosage forms and methods of making and using same |
| abstract |
Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9114103-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9345679-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9707253-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015110839-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018098976-A1 |
| priorityDate |
2008-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |